Ex­clu­sive: Joe Jimenez's Adi­tum Bio rings in new year with $428M third fund

The first bio­phar­ma ven­ture fund to close in 2025 comes from in­dus­try vet­er­ans Joe Jimenez and Mark Fish­man, two for­mer No­var­tis lead­ers.

Jimenez ex­clu­sive­ly told …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER